CD138 Antibody (Rabbit Monoclonal)

Product Description

CD138 Antibody (Rabbit Monoclonal)
Catalog number: B2010602
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 100 uL
Molecular Weight or Concentration: na
Supplied as: Solution
Applications: molecular tool in the study of CD138
Storage: -20C
Keywords: Anti-CD138 antibody
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1: Palaiologou M, Delladetsima I, Tiniakos D. CD138 (syndecan-1) expression in
health and disease. Histol Histopathol. 2014 Feb;29(2):177-89.

2: Yu T, Chaganty B, Lin L, Xing L, Ramakrishnan B, Wen K, Hsieh PA, Wollacott
A, Viswanathan K, Adari H, Cho SF, Li Y, Chen H, Yang W, Xu Y, An G, Qiu L,
Munshi N, Babcock G, Shriver Z, Myette JR, Anderson KC, Tai YT. VIS832, a novel
CD138-targeting monoclonal antibody, potently induces killing of human multiple
myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo.
Blood Cancer J. 2020 Nov 2;10(11):110.

3: Pracht K, Meinzinger J, Daum P, Schulz SR, Reimer D, Hauke M, Roth E, Mielenz
D, Berek C, Côrte-Real J, Jäck HM, Schuh W. A new staining protocol for
detection of murine antibody-secreting plasma cell subsets by flow cytometry.
Eur J Immunol. 2017 Aug;47(8):1389-1392.

4: Halliley JL, Tipton CM, Liesveld J, Rosenberg AF, Darce J, Gregoretti IV,
Popova L, Kaminiski D, Fucile CF, Albizua I, Kyu S, Chiang KY, Bradley KT,
Burack R, Slifka M, Hammarlund E, Wu H, Zhao L, Walsh EE, Falsey AR, Randall TD,
Cheung WC, Sanz I, Lee FE. Long-Lived Plasma Cells Are Contained within the
CD19(-)CD38(hi)CD138(+) Subset in Human Bone Marrow. Immunity. 2015 Jul
21;43(1):132-45.

5: Sherbenou DW, Behrens CR, Su Y, Wolf JL, Martin TG 3rd, Liu B. The
development of potential antibody-based therapies for myeloma. Blood Rev. 2015
Mar;29(2):81-91.
6: Lee L, Bounds D, Paterson J, Herledan G, Sully K, Seestaller-Wehr LM, Fieles
WE, Tunstead J, McCahon L, Germaschewski FM, Mayes PA, Craigen JL, Rodriguez-
Justo M, Yong KL. Evaluation of B cell maturation antigen as a target for
antibody drug conjugate mediated cytotoxicity in multiple myeloma. Br J
Haematol. 2016 Sep;174(6):911-22.

7: Lancman G, Richter J, Chari A. Bispecifics, trispecifics, and other novel
immune treatments in myeloma. Hematology Am Soc Hematol Educ Program. 2020 Dec
4;2020(1):264-271.
8: Liu L, Takeda K, Akkoyunlu M. Disease Stage-Specific Pathogenicity of CD138
(Syndecan 1)-Expressing T Cells in Systemic Lupus Erythematosus. Front Immunol.
2020 Jul 28;11:1569.

9: Kind S, Kluth M, Hube-Magg C, Möller K, Makrypidi-Fraune G, Lutz F, Lennartz
M, Rico SD, Schlomm T, Heinzer H, Höflmayer D, Weidemann S, Uhlig R, Huland H,
Graefen M, Bernreuther C, Tsourlakis MC, Minner S, Dum D, Hinsch A, Lübke AM,
Simon R, Sauter G, Marx A, Polonski A. Increased Cytoplasmic CD138 Expression Is
Associated with Aggressive Characteristics in Prostate Cancer and Is an
Independent Predictor for Biochemical Recurrence. Biomed Res Int. 2020 Oct
28;2020:5845374.
10: Mykytiv V, Alwaheed A, Mohd Hashim NA. Double
CD38^–/CD138^– negative multiple myeloma. Hematol Oncol Stem
Cell Ther. 2019 Mar;12(1):64-66.

Products Related to CD138 Antibody (Rabbit Monoclonal): Antibodies